Jiri Kettner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiri Kettner has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
J. Kautzner
3 shared publications- Ivo Skalsky
Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague 4, Czech Republic
2 shared publications A. Filipecki
1 shared publicationA. Silva
1 shared publication- Antonín Jabor
Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
1 shared publication B. Aldhoon
1 shared publication
Latest Publications
- 1 June 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 446, 128-131
A clinical and laboratory approach used to elucidate discordant results of high-sensitivity troponin T and troponin I
- 1 June 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 446, 128-131
A clinical and laboratory approach used to elucidate discordant results of high-sensitivity troponin T and troponin I
- 1 December 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (11) , 1709-1713
Utility of Intra-Aortic Balloon Pump Support for Ventricular Septal Rupture and Acute Mitral Regurgitation Complicating Acute Myocardial Infarction
- 1 December 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (11) , 1709-1713
Utility of Intra-Aortic Balloon Pump Support for Ventricular Septal Rupture and Acute Mitral Regurgitation Complicating Acute Myocardial Infarction
- 17 October 2011
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 60 (5) , 769-775
Is Severe Pulmonary Hypertension a Contraindication for Orthotopic Heart Transplantation? Not Any More
Pulmonary hypertension (PH) unresponsive to pharmacological intervention is considered a contraindication for orthotopic heart transplantation (OHTX) due to risk of postoperative right-heart failure. In this prospective study, we describe our experience with a treatment strategy of improving severe PH in heart transplant candidates by means of ventricular assist device (VAD) implantation and subsequent OHTX. In 11 heart transplantation candidates with severe PH unresponsive to pharmacological intervention we implanted VAD with the aim of achieving PH to values acceptable for OHTX. In all patients we observed significant drop in pulmonary pressures, PVR and TPG (p
- 17 October 2011
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 60 (5) , 769-775
Is Severe Pulmonary Hypertension a Contraindication for Orthotopic Heart Transplantation? Not Any More
Pulmonary hypertension (PH) unresponsive to pharmacological intervention is considered a contraindication for orthotopic heart transplantation (OHTX) due to risk of postoperative right-heart failure. In this prospective study, we describe our experience with a treatment strategy of improving severe PH in heart transplant candidates by means of ventricular assist device (VAD) implantation and subsequent OHTX. In 11 heart transplantation candidates with severe PH unresponsive to pharmacological intervention we implanted VAD with the aim of achieving PH to values acceptable for OHTX. In all patients we observed significant drop in pulmonary pressures, PVR and TPG (p
- 1 February 2011
- Published by IMR Press in The Heart Surgery Forum
- Vol. 14 (1) , 64-6
Levitronix CentriMag Pump as Perioperative Left Ventricular Support in a Patient with Critical Aortic Stenosis, Mitral Regurgitation, and Cardiogenic Shock
Severe aortic stenosis (AS) has a poor prognosis when associated with left ventricular dysfunction and congestive heart failure. Despite a relatively high operative mortality, most patients with severe AS and a depressed left ventricular ejection fraction (LVEF) should be considered candidates for aortic valve replacement. The CentriMag left ventricular assist system (Levitronix) can be used for perioperative or postcardiotomy circulatory support for the failing heart. In this case report, we report the successful use of the Levitronix CentriMag device as perioperative support in a high-risk patient with severe AS, significant mitral insufficiency, and a poor LVEF with advanced organ failure.
- 1 February 2011
- Published by IMR Press in The Heart Surgery Forum
- Vol. 14 (1) , 64-6
Levitronix CentriMag Pump as Perioperative Left Ventricular Support in a Patient with Critical Aortic Stenosis, Mitral Regurgitation, and Cardiogenic Shock
Severe aortic stenosis (AS) has a poor prognosis when associated with left ventricular dysfunction and congestive heart failure. Despite a relatively high operative mortality, most patients with severe AS and a depressed left ventricular ejection fraction (LVEF) should be considered candidates for aortic valve replacement. The CentriMag left ventricular assist system (Levitronix) can be used for perioperative or postcardiotomy circulatory support for the failing heart. In this case report, we report the successful use of the Levitronix CentriMag device as perioperative support in a high-risk patient with severe AS, significant mitral insufficiency, and a poor LVEF with advanced organ failure.
- Open Access
- 25 May 2010
- Published by Springer Nature in Trials
- Vol. 11 (1) , 61
Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)
Statins have been proved to be effective in reduction of mortality and morbidity when started in the early secondary prevention in stabilized patients after acute coronary syndrome (ACS). The safety and efficacy of statin administration directly in the first-line therapy in unstable ACS patients is not clear. The aim of our study was, therefore, to assess the effect of statin treatment initiated immediately at hospital admission of patients with ACS.
- 25 May 2010
- Published by Springer Nature in Trials
- Vol. 11 (1) , 61
Open AccessFluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)
Statins have been proved to be effective in reduction of mortality and morbidity when started in the early secondary prevention in stabilized patients after acute coronary syndrome (ACS). The safety and efficacy of statin administration directly in the first-line therapy in unstable ACS patients is not clear. The aim of our study was, therefore, to assess the effect of statin treatment initiated immediately at hospital admission of patients with ACS.
- 1 January 2010
- Vol. 56 (1) , 30-6
[Right ventricular dysfunction after left ventricular assist device implantation].
The frequency of long-term left ventricular assist device (LVAD) implantation is increasing. Acute right ventricular dysfunction or right ventricular failure after LVAD implantation has important influence on morbidity and mortality. The aim of our study was to assess the management of right ventricular dysfunction after LVAD implantation. The study group comprised 21 patients with implanted HeartMate II LVAD since December, 2006 to April, 2009. We evaluated in retrospective fashion baseline parameters of cardiovascular and other organ systems before LVAD implantation, applied pharmacological and mechanical support for the right ventricle, and important clinical outcomes to the end ofJune, 2009. LVAD was implanted in 18 men and 3 women with mean age of 48.7 +/- 11.2 years. The most frequent diagnosis was dilatational cardiomyopathy (9 patients; 42.9%), and the most frequent indication for implantation was bridge-to-transplantation (19 patients; 90.4%). Pharmacological support of the right ventricle after LVAD implantation comprised dobutamine (21 patients; 100%), milrinone (21 patients; 100%), isoproterenol (1 patient; 4.8%), and levosimendan (5 patients; 23.8%). In 2 (9.5%) cases there was a need for repeated application of levosimendan during postoperative course. Inhalational nitric oxide was used in 14 (66.7%) patients. Despite extensive pharmacological support, 3 (14.3%) patients needed right ventricular assist device (RVAD) implantation. Most patients (9; 42.8%) survived to heart transplantation; in one (4.8%) case LVAD was successfuly explanted; 6 (28.6%) patients is living with LVAD; 5 (23.8%) patients died during LVAD support. After LVAD implantation there is a need for aggressive pharmacological, and in some cases mechanical, support of the right ventricular function to provide adequate blood flow to LVAD in order to minimize morbidity and mortality.
- 1 January 2010
- Vol. 56 (1) , 30-6
[Right ventricular dysfunction after left ventricular assist device implantation].
The frequency of long-term left ventricular assist device (LVAD) implantation is increasing. Acute right ventricular dysfunction or right ventricular failure after LVAD implantation has important influence on morbidity and mortality. The aim of our study was to assess the management of right ventricular dysfunction after LVAD implantation. The study group comprised 21 patients with implanted HeartMate II LVAD since December, 2006 to April, 2009. We evaluated in retrospective fashion baseline parameters of cardiovascular and other organ systems before LVAD implantation, applied pharmacological and mechanical support for the right ventricle, and important clinical outcomes to the end ofJune, 2009. LVAD was implanted in 18 men and 3 women with mean age of 48.7 +/- 11.2 years. The most frequent diagnosis was dilatational cardiomyopathy (9 patients; 42.9%), and the most frequent indication for implantation was bridge-to-transplantation (19 patients; 90.4%). Pharmacological support of the right ventricle after LVAD implantation comprised dobutamine (21 patients; 100%), milrinone (21 patients; 100%), isoproterenol (1 patient; 4.8%), and levosimendan (5 patients; 23.8%). In 2 (9.5%) cases there was a need for repeated application of levosimendan during postoperative course. Inhalational nitric oxide was used in 14 (66.7%) patients. Despite extensive pharmacological support, 3 (14.3%) patients needed right ventricular assist device (RVAD) implantation. Most patients (9; 42.8%) survived to heart transplantation; in one (4.8%) case LVAD was successfuly explanted; 6 (28.6%) patients is living with LVAD; 5 (23.8%) patients died during LVAD support. After LVAD implantation there is a need for aggressive pharmacological, and in some cases mechanical, support of the right ventricular function to provide adequate blood flow to LVAD in order to minimize morbidity and mortality.
- Open Access
- 1 June 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (Supplement)
Poster Session 2: Secondary prevention
Introduction: Idiopathic ventricular tachycardia (VT) and fibrillation (VF) are rare conditions diagnosed after exclusion of structural heart disease and primary electrical disease (Brugada syndrome and long QT syndrome, among others).
- 1 June 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (Supplement)
Open AccessPoster Session 2: Secondary prevention
Introduction: Idiopathic ventricular tachycardia (VT) and fibrillation (VF) are rare conditions diagnosed after exclusion of structural heart disease and primary electrical disease (Brugada syndrome and long QT syndrome, among others).
- Open Access
- 1 January 2001
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 2 (Supplement) , A54
Influence of improved left ventricular function following elective ptca of a single myocardial infarction-related coronary artery on heart rate variability indices
J. Kautzner, L. Nečasová, J. Kettner; Influence of improved left ventricular function following elective ptca of a single myocardial infarction-related coronar
- 1 January 2001
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 2 (Supplement) , A54
Open AccessInfluence of improved left ventricular function following elective ptca of a single myocardial infarction-related coronary artery on heart rate variability indices
J. Kautzner, L. Nečasová, J. Kettner; Influence of improved left ventricular function following elective ptca of a single myocardial infarction-related coronar